US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm Alloy Therapeutics Inc. The alliance is designed to develop a new platform aimed at enhancing Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.
Deal Terms and Collaboration
Under the terms of the deal, Alloy Therapeutics will receive an undisclosed upfront payment from Pfizer and will be eligible for pre-specified milestones from preclinical to commercial stages for products originating from the newly developed platform. The two companies have previously collaborated on antibody discovery, including the use of Alloy’s ATX-CLC platform to develop light chain antibodies, which facilitates efficient and modular bispecific antibody discovery.-Fineline Info & Tech
